We recently identified another mechanism of HER2 activation, assessed by HER2 phosphorylation (pHER2), and regulated by fragile histidine triad (FHIT), a tumor suppressor frequently lost in NSCLC (7, 8). The gene discussed is ERBB2; the disease is neoplasm.